Relay Therapeutics, Inc. (NASDAQ: RLAY) reported Q2 EPS of ($0.41), $0.08 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $700 thousand versus the consensus estimate of $66.67 thousand.

For earnings history and earnings-related data on Relay Therapeutics, Inc. (RLAY) click here.